VivoSeq
Metabolic & Endocrine

Type 2 Diabetes (T2DM)

4

Pipeline Programs↗

5

Active Trials↗

5

Companies Involved↗

Type 2 Diabetes (T2DM) is an early-stage landscape with 4 programs across 5 companies. The most active players are AstraZeneca, Novartis, Gan & Lee Pharmaceuticals.. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

30/100

Pipeline Velocity

22/100

Mech. Concentration

50/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2G

Gan & Lee Pharmaceuticals.

1 program

Phase 3G

Gan and Lee Pharmaceuticals, USA

1 program

Phase 3N

Nazarii Kobyliak

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

5

clinical trials

Not yet recruiting2 · 40%
Recruiting2 · 40%
Enrolling by invitation1 · 20%

Clinical Trials

Trial Activity

A Double-Blind, Randomized, Active-Controlled Phase 2a Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of TriGlytza®-01 in Overweight and Obese Adults With Type 2 Diabetes and Inadequate Glycaemic Control Despite Metformin Therapy
Not yet recruiting·MMyopharm Limited·Phase 2·NCT07139405·48 enrolled
Evaluation of Continuous Glucose Monitoring Systems for Optimizing Glycemic Control in Patients With Newly Diagnosed Type 2 Diabetes: A Postmarketing Clinical Analysis
Recruiting·—·Preclinical·NCT07690163·80 enrolled
Hepatocellular Carcinoma Risk Assessment and Surveillance in Patients With Type 2 Diabetes
Not yet recruiting·NNational Taiwan University Hospital·Preclinical·NCT07675187·2,400 enrolled
A Randomized, Open-label, Parallel-controlled, Multicenter Phase III Clinical Study Comparing the Efficacy and Safety of GZR33 Injection and Insulin Degludec Injection in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antidiabetic Drugs
Recruiting·GGan & Lee Pharmaceuticals.·Phase 3·NCT07527078·350 enrolled
Remission Evaluation of Metabolic Interventions in Type 2 Diabetes in Primary Care (REMIT-Prime): An Implementation-effectiveness Study
Enrolling by invitation·MMcMaster University·N/A·NCT07665567·118 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)